“Title of publication” Journal, Year

Penn investigators involved (*lead)

What we learned

“A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis”

Arthritis & Rheumatology, 2017

Dr. Peter Merkel*

Dr. Antoine Sreih

“Infections and the risk of incident giant cell arteritis: a population-based, case-control study”

Annals of the Rheumatic Diseases, 2017

Dr. Rennie Rhee*

Dr. Peter Merkel

- Patients with GCA who received abatacept in addition to prednisone were less likely to relapse and had more months in remission

- Antecedent infections are modestly associated with the development of GCA